New hope for advanced cancers? TAK-505 trial begins

NCT ID NCT07436728

First seen Mar 04, 2026 · Last updated May 15, 2026 · Updated 6 times

Summary

This study tests a new drug called TAK-505 for the first time in people with advanced solid tumors that cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink or slow tumor growth. About 151 adults with certain cancers like stomach, colorectal, lung, or head and neck cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Baylor College of Medicine

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cleveland Clinic Foundation

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • H Lee Moffitt Cancer Center

    NOT_YET_RECRUITING

    Tampa, Florida, 33612, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Icahn School of Medicine at Mount Sinai

    NOT_YET_RECRUITING

    New York, New York, 10029, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MD Anderson

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mary Crowley Cancer Center

    NOT_YET_RECRUITING

    Dallas, Texas, 75230, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Oncology

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Oncology

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sarah Cannon Research Institute SCRI

    NOT_YET_RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Seattle Cancer Care Alliance

    NOT_YET_RECRUITING

    Seattle, Washington, 98109, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tennessee Oncology

    NOT_YET_RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UCI Health

    NOT_YET_RECRUITING

    Orange, California, 92868, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Univeristy of Minnesota

    NOT_YET_RECRUITING

    Minneapolis, Minnesota, 55455, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California San Diego Medical Center, La Jolla

    NOT_YET_RECRUITING

    San Diego, California, 92093, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California San Francisco

    NOT_YET_RECRUITING

    San Francisco, California, 94143, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.